Since its founding in 2016, Certis has offered personalized functional testing to help inform individual cancer treatment decisions, an approach gaining wide support from cancer researchers and oncology clinicians worldwide. Using our patent-pending artificial intelligence/machine learning platform, and more clinically relevant, patient-derived tumor models, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/17/24 | $10,000,000 | Series C |
Cambridge Investments | undisclosed |
